Department of Error

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376: 1658–69—In the Results section of this Article (Nov 13), the risk ratio for coronary revascularisation presented in the fifth paragraph should have been 0·93 (0·83–1·04), and in final sentence of this paragraph, the percentage of patients allocated 20 mg simvastatin reported to have had transient cerebral ischaemic attacks was 2·5%. In the seventh paragraph of this section, the numbers of female breast cancers in the other trials of statin versus control should have been 194 (1·0%) vs 187 (1·0%). Furthermore, the second sentence of the final paragraph of the Results section should have read “New diabetes was reported by 625 (11·6%) participants allocated 80 mg simvastatin versus 587 (10·9%) allocated 20 mg simvastatin (RR 1·07, 0·95–1·19)”. In the second paragraph of the Discussion, the p value for comparison of non-vascular deaths on 80 mg versus 10 mg atorvastatin should have been 0·06. These corrections have been made to the online version as of Nov 25, 2010.